The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo

BACKGROUND: Mechanisms by which Smac mimetics (SMs) interact with proteasome inhibitors (e.g., bortezomib) are largely unknown, particularly in multiple myeloma (MM), a disease in which bortezomib represents a mainstay of therapy. METHODS: Interactions between the clinically relevant IAP (inhibitor...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Hematol Oncol
Glavni autori: Zhou, Liang, Zhang, Yu, Leng, Yun, Dai, Yun, Kmieciak, Maciej, Kramer, Lora, Sharma, Kanika, Wang, Yan, Craun, William, Grant, Steven
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2019
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6407248/
https://ncbi.nlm.nih.gov/pubmed/30845975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-019-0713-x
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items